Keyphrases
Drug Discovery
67%
Molecular Targets
67%
Visceral Leishmaniasis
66%
Mode of Action
64%
LysR Family
62%
Chagas Disease
59%
Leishmania Donovani
57%
Human African Trypanosomiasis
56%
Thermal Proteome Profiling
53%
Trypanosoma Cruzi (T. cruzi)
51%
Phenotypic Screening
38%
Target Engagement
37%
Diaminothiazoles
37%
Preclinical Candidate
37%
Plasmodium Falciparum
37%
Cryptosporidium
37%
Drug Target
35%
Leishmania
32%
Resistance mutations
29%
Pullout
28%
Mass Spectrometry
28%
Antileishmanial Compounds
28%
Current Treatment
27%
Mechanism of Action
26%
Rapid Assessment
24%
Pyrrolopyrimidine
24%
Short Course
24%
Cytochrome bc1 Complex
24%
Clinical Development
24%
Benzoxaborole
23%
CYP51
22%
Treatment Options
20%
Neglected Tropical Diseases
20%
Pharmacokinetic Properties
19%
Cell-free Lysate
18%
Phosphorylation
18%
Cyclin A
18%
Oxaboroles
18%
Resistance Factor
18%
Antileishmanial
18%
Imaging Rate
18%
Proline
18%
Compound Profiling
18%
Aryl Aldehydes
18%
Cks1
18%
Cyclin-dependent Kinase 1 (CDK1)
18%
Resistance Mapping
18%
Sterols
18%
Cyclin-dependent Kinase
18%
Chronic Chagas Disease
18%
Chagas Disease Drug Discovery
18%
Drug Resistance mutations
18%
Death Rate
18%
Anti-trypanosomatid Drugs
18%
Selection Marker
18%
Relative Fitness
18%
Benznidazole
18%
Combination Treatment
18%
Demethylase
18%
Multidrug-resistant
18%
Cross-resistance
18%
Preclinical Development
18%
Trypanosomatids
18%
High-content Assay
18%
Kinetoplastid
18%
Oligo
18%
Cytochrome P450 Reductase
18%
Live Imaging
18%
Leucyl Aminopeptidase
18%
Plasmodium
18%
Leishmania Major
18%
Parallel Profiling
18%
Specific Resistance
18%
Saturation mutagenesis
18%
Resistance Profiling
18%
Anticryptosporidial
18%
Efficacy in Vivo
18%
Protozoan Parasites
18%
Parasitic Diseases
17%
Specificity Factor
17%
Alternative Polyadenylation
17%
Drug Resistance
17%
Resistant Clones
15%
New Medicines
15%
Chemotype
15%
Drug-treated
15%
Malaria
15%
Neglected Diseases
14%
Putative Targets
14%
L. Major
14%
Resistance Mechanisms
13%
Lack of Understanding
13%
Cattle
12%
Malic Enzyme
12%
Trypanosoma Vivax
12%
Codon
12%
Trypanosoma Congolense
12%
Lysate
12%
Cytochrome b
12%
T. Brucei
12%
Parasite Burden
12%
Cryptosporidiosis
12%
Amphotericin B
11%
Drug Development
10%
Multiple Regions
10%
Leishmaniasis
10%
Overexpression
10%
Reduced Susceptibility
10%
In Vivo Efficacy
9%
New Drugs
9%
Causative Agents
9%
New Chemical Entities
9%
Trypanosoma Brucei
9%
Ligand Soaking
9%
Promising Target
9%
Cosmid
9%
Biologically Relevant
9%
Target Validation
9%
Resistant mutants
9%
Structural Information
9%
Profiling Method
9%
Compound Optimization
9%
Interacting Proteins
9%
High-resolution
9%
Protein Thermal Stability
9%
Focused Approach
9%
Validation Strategies
9%
Chemical Probes
9%
Antimalarial Drug Discovery
9%
Tandem Mass Tag Labeling
9%
Monitoring Change
9%
Thermal Stability
9%
Cell Lysate
9%
Protocol Optimization
9%
Multiple Cell Lines
9%
Protein Targeting
9%
Intracellular Amastigotes
9%
Selective Inhibitor
9%
Calf Model
9%
Compound Properties
9%
Potential Treatments
9%
Leading Causes of Death
9%
Mouse Infection
9%
Clinical High Risk
9%
Nitazoxanide
9%
Infection Model
9%
Immunodeficient Mice
9%
Unmet Medical Need
9%
Preclinical Safety Studies
9%
Diarrheal Disease
9%
Mouse Model
9%
Neglected Infectious Diseases
9%
Gastrointestinal Infection
9%
Knowledge Gaps
9%
Physicochemical Properties
9%
Low-middle Income Countries
8%
Target Identification
8%
Drug-like
8%
Total Sterols
7%
HyPer
7%
Cytocidal
7%
Clinical Trials
7%
Intracellular Parasites
7%
Ergosterol
7%
New Therapeutics
7%
In Vivo Antileishmanial Activity
6%
CPSF3
6%
Balanced Portfolio
6%
Trans-signaling
6%
Site-saturation mutagenesis
6%
Precise Editing
6%
Improved Genetic
6%
Antichagasic Drug
6%
Scalable Precision
6%
Development pipeline
6%
Mechanism of Action Studies
6%
Target Candidate Profile
6%
Complex Inhibitor
6%
Leishmaniasis Visceral
6%
Intramuscular Therapy
6%
Days of Treatment
6%
Quantitative Proteomics
6%
Targeted Drugs
6%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
6%
Resin
6%
Recent Advances
6%
Acceptable Safety
6%
Causative Pathogen
6%
New Drug Candidate
6%
Genetic Engineering
6%
Drug Efficacy
6%
Mismatch Repair
6%
On-state Current
6%
Pharmacophore
6%
Animal Models of Infection
6%
Targeted Methods
6%
LC-MS Analysis
6%
Drug Action
6%
Endonuclease
6%
Action Targets
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chagas Disease
90%
Drug Discovery
67%
Visceral Leishmaniasis
57%
African Trypanosomiasis
53%
Leishmania
39%
Trypanosomatidae
37%
Lysine Transfer RNA Ligase
37%
Cryptosporidium
37%
Infection
34%
Molecular Target
29%
Protozoon
28%
Tropical Disease
26%
Coenzyme Q - Cytochrome C Reductase
24%
Proteasome
24%
Lead Compound
24%
Cyclin Dependent Kinase
24%
Drug Resistance
24%
Trypanosoma Cruzi
24%
Hexachlorophene
18%
Acoziborole
18%
Clinical Trial
18%
Kinetoplastida
18%
Benznidazole
18%
Cytosol Aminopeptidase
18%
Leishmania Major
18%
Nagana
18%
Cleavage and Polyadenylation Specificity Factor
17%
Pharmacokinetics
14%
Parasitosis
12%
Malate Dehydrogenase (Decarboxylating)
12%
Cytochrome B
12%
Bovine
12%
Target Identification
12%
Neglected Disease
10%
Leishmaniasis
10%
Trypanosoma Brucei
9%
Drug Development
9%
Amastigote
9%
Mouse Model
9%
Diseases
9%
Cytostatic Agent
7%
Cryptosporidiosis
7%
Disease
6%
Skin Leishmaniasis
6%
Chymotrypsin
6%
Proteasome Inhibitor
6%
Infectious Agent
6%
Lanosterol 14 Alpha-Demethylase
6%
Side Effect
6%
Nifurtimox
6%
Oligodeoxynucleotide
6%
Enzyme Inhibition
6%
Trypanosoma Vivax
6%
Combination Therapy
6%
Endonuclease
6%
Epimastigote
6%
Pharmaceutical Chemistry
6%
Antitrypanosomal
6%
Mutagenesis
6%
Amino Acid
6%
Leishmania donovani
6%
Trypanosoma Congolense
6%
Base
6%
Intramuscular Injection
6%
Toxicology
6%
Immunology and Microbiology
Chagas Disease
100%
Visceral Leishmaniasis
72%
Parasitology
62%
Leishmania donovani
43%
Trypanosomatid
37%
Antimalarial Agent
37%
Drug Resistance
34%
Protozoa
34%
Trypanosoma Cruzi
26%
Chemotype
24%
Proteasome
24%
Wild Type
24%
Mutagenesis
24%
Cryptosporidium
18%
Kinetoplastida
18%
Cosmid
18%
Plasmodium falciparum
18%
Cross-Resistance
18%
Trans-Splicing
18%
Benznidazole
18%
Intracellular Parasite
18%
Plasmodium
18%
DNA Template
18%
Transfer RNA
18%
Polyadenylation
18%
Neglected Disease
16%
Codon
12%
Cell Line
12%
Parasitic Disease
12%
Leishmania
12%
Amastigote
9%
Plasmid
9%
Cell Population
9%
Genetic Transfection
9%
Infectious Disease
6%
Parasite Load
6%
DNA Barcoding
6%
Cycline
6%
Mismatch Repair
6%
Leishmaniasis
6%
EC50
6%
Drug Activity
6%
Respiratory Chain
6%
Cutaneous Leishmaniasis
6%
Promastigote
6%
Resistant Cell Line
6%
Drug Exposure
6%
in Vitro Selection
6%
Qi
6%
Chromosome 2
6%
Drug Efficacy
6%
Infectious Agent
6%
Illumina Dye Sequencing
6%
Amplicon Sequencing
6%
Solution and Solubility
6%
Trypanosoma Brucei
6%
Life Cycle
5%